Dimiter S. Dimitrov, Frederick, MD (US); Zhongyu Zhu, Frederick, MD (US); Bradley St. Croix, Frederick, MD (US); Steven Seaman, Martinsburg, WV (US); Saurabh Saha, Wellesley Hills, MA (US); Xiaoyan Michelle Zhang, Lexington, MA (US); Gary A. DeCrescenzo, Parkville, MO (US); and Dean Welsch, Parkville, MO (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and BioMed Valley Discoveries, Inc., Kansas City, MO (US)
Filed by THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH, Bethesda, MD (US); and BIOMED VALLEY DISCOVERIES, INC., Kansas City, MO (US)
Filed on Mar. 9, 2020, as Appl. No. 16/812,980.
Application 16/812,980 is a division of application No. 15/512,000, granted, now 10,604,582, previously published as PCT/US2015/050365, filed on Sep. 16, 2015.
Claims priority of provisional application 62/051,650, filed on Sep. 17, 2014.
Prior Publication US 2020/0199246 A1, Jun. 25, 2020
1. A conjugate comprising (a) an anti-CD276 binding moiety conjugated to (b) an effector molecule, wherein the anti-CD276 binding moiety comprises the amino acid sequences of (i) SEQ ID NOs: 7 and 8, or (ii) SEQ ID NOs: 17 and 18.